Androgen receptor splice variants determine taxane sensitivity in prostate cancer

Maria Thadani-Mulero, Luigi Portella, Shihua Sun, Matthew Sung, Alexandre Matov, Robert L. Vessella, Eva Corey, David M. Nanus, Stephen R. Plymate, Paraskevi Giannakakou

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Prostate cancer growth depends on androgen receptor signaling. Androgen ablation therapy induces expression of constitutively active androgen receptor splice variants that drive disease progression. Taxanes are a standard of care therapy in castration-resistant prostate cancer (CRPC); however, mechanisms underlying the clinical activity of taxanes are poorly understood. Recent work suggests that the microtubule network of prostate cells is critical for androgen receptor nuclear translocation and activity. In this study, we used a set of androgen receptor deletion mutants to identify the microtubule-binding domain of the androgen receptor, which encompasses the DNA binding domain plus hinge region. We report that two clinically relevant androgen receptor splice variants, ARv567 and ARv7, differentially associate with microtubules and dynein motor protein, thereby resulting in differential taxane sensitivity in vitro and in vivo. ARv7, which lacks the hinge region, did not co-sediment with microtubules or coprecipitate with dynein motor protein, unlike ARv567. Mechanistic investigations revealed that the nuclear accumulation and transcriptional activity of ARv7 was unaffected by taxane treatment. In contrast, the microtubule-interacting splice variant ARv567 was sensitive to taxane-induced microtubule stabilization. In ARv567-expressing LuCap86.2 tumor xenografts, docetaxel treatment was highly efficacious, whereas ARv7-expressing LuCap23.1 tumor xenografts displayed docetaxel resistance. Our results suggest that androgen receptor variants that accumulate in CRPC cells utilize distinct pathways of nuclear import that affect the antitumor efficacy of taxanes, suggesting a mechanistic rationale to customize treatments for patients with CRPC, which might improve outcomes.

Original languageEnglish
Pages (from-to)2270-2282
Number of pages13
JournalCancer Research
Volume74
Issue number8
DOIs
Publication statusPublished - Apr 15 2014

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Microtubules
docetaxel
Taxoids
Castration
Dyneins
Heterografts
Therapeutics
Cell Nucleus Active Transport
Standard of Care
taxane
Androgens
Disease Progression
Prostate
Neoplasms
Proteins
DNA
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thadani-Mulero, M., Portella, L., Sun, S., Sung, M., Matov, A., Vessella, R. L., ... Giannakakou, P. (2014). Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Research, 74(8), 2270-2282. https://doi.org/10.1158/0008-5472.CAN-13-2876

Androgen receptor splice variants determine taxane sensitivity in prostate cancer. / Thadani-Mulero, Maria; Portella, Luigi; Sun, Shihua; Sung, Matthew; Matov, Alexandre; Vessella, Robert L.; Corey, Eva; Nanus, David M.; Plymate, Stephen R.; Giannakakou, Paraskevi.

In: Cancer Research, Vol. 74, No. 8, 15.04.2014, p. 2270-2282.

Research output: Contribution to journalArticle

Thadani-Mulero, M, Portella, L, Sun, S, Sung, M, Matov, A, Vessella, RL, Corey, E, Nanus, DM, Plymate, SR & Giannakakou, P 2014, 'Androgen receptor splice variants determine taxane sensitivity in prostate cancer', Cancer Research, vol. 74, no. 8, pp. 2270-2282. https://doi.org/10.1158/0008-5472.CAN-13-2876
Thadani-Mulero, Maria ; Portella, Luigi ; Sun, Shihua ; Sung, Matthew ; Matov, Alexandre ; Vessella, Robert L. ; Corey, Eva ; Nanus, David M. ; Plymate, Stephen R. ; Giannakakou, Paraskevi. / Androgen receptor splice variants determine taxane sensitivity in prostate cancer. In: Cancer Research. 2014 ; Vol. 74, No. 8. pp. 2270-2282.
@article{ff3703f2867f48c399bec4c68052351c,
title = "Androgen receptor splice variants determine taxane sensitivity in prostate cancer",
abstract = "Prostate cancer growth depends on androgen receptor signaling. Androgen ablation therapy induces expression of constitutively active androgen receptor splice variants that drive disease progression. Taxanes are a standard of care therapy in castration-resistant prostate cancer (CRPC); however, mechanisms underlying the clinical activity of taxanes are poorly understood. Recent work suggests that the microtubule network of prostate cells is critical for androgen receptor nuclear translocation and activity. In this study, we used a set of androgen receptor deletion mutants to identify the microtubule-binding domain of the androgen receptor, which encompasses the DNA binding domain plus hinge region. We report that two clinically relevant androgen receptor splice variants, ARv567 and ARv7, differentially associate with microtubules and dynein motor protein, thereby resulting in differential taxane sensitivity in vitro and in vivo. ARv7, which lacks the hinge region, did not co-sediment with microtubules or coprecipitate with dynein motor protein, unlike ARv567. Mechanistic investigations revealed that the nuclear accumulation and transcriptional activity of ARv7 was unaffected by taxane treatment. In contrast, the microtubule-interacting splice variant ARv567 was sensitive to taxane-induced microtubule stabilization. In ARv567-expressing LuCap86.2 tumor xenografts, docetaxel treatment was highly efficacious, whereas ARv7-expressing LuCap23.1 tumor xenografts displayed docetaxel resistance. Our results suggest that androgen receptor variants that accumulate in CRPC cells utilize distinct pathways of nuclear import that affect the antitumor efficacy of taxanes, suggesting a mechanistic rationale to customize treatments for patients with CRPC, which might improve outcomes.",
author = "Maria Thadani-Mulero and Luigi Portella and Shihua Sun and Matthew Sung and Alexandre Matov and Vessella, {Robert L.} and Eva Corey and Nanus, {David M.} and Plymate, {Stephen R.} and Paraskevi Giannakakou",
year = "2014",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-13-2876",
language = "English",
volume = "74",
pages = "2270--2282",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Androgen receptor splice variants determine taxane sensitivity in prostate cancer

AU - Thadani-Mulero, Maria

AU - Portella, Luigi

AU - Sun, Shihua

AU - Sung, Matthew

AU - Matov, Alexandre

AU - Vessella, Robert L.

AU - Corey, Eva

AU - Nanus, David M.

AU - Plymate, Stephen R.

AU - Giannakakou, Paraskevi

PY - 2014/4/15

Y1 - 2014/4/15

N2 - Prostate cancer growth depends on androgen receptor signaling. Androgen ablation therapy induces expression of constitutively active androgen receptor splice variants that drive disease progression. Taxanes are a standard of care therapy in castration-resistant prostate cancer (CRPC); however, mechanisms underlying the clinical activity of taxanes are poorly understood. Recent work suggests that the microtubule network of prostate cells is critical for androgen receptor nuclear translocation and activity. In this study, we used a set of androgen receptor deletion mutants to identify the microtubule-binding domain of the androgen receptor, which encompasses the DNA binding domain plus hinge region. We report that two clinically relevant androgen receptor splice variants, ARv567 and ARv7, differentially associate with microtubules and dynein motor protein, thereby resulting in differential taxane sensitivity in vitro and in vivo. ARv7, which lacks the hinge region, did not co-sediment with microtubules or coprecipitate with dynein motor protein, unlike ARv567. Mechanistic investigations revealed that the nuclear accumulation and transcriptional activity of ARv7 was unaffected by taxane treatment. In contrast, the microtubule-interacting splice variant ARv567 was sensitive to taxane-induced microtubule stabilization. In ARv567-expressing LuCap86.2 tumor xenografts, docetaxel treatment was highly efficacious, whereas ARv7-expressing LuCap23.1 tumor xenografts displayed docetaxel resistance. Our results suggest that androgen receptor variants that accumulate in CRPC cells utilize distinct pathways of nuclear import that affect the antitumor efficacy of taxanes, suggesting a mechanistic rationale to customize treatments for patients with CRPC, which might improve outcomes.

AB - Prostate cancer growth depends on androgen receptor signaling. Androgen ablation therapy induces expression of constitutively active androgen receptor splice variants that drive disease progression. Taxanes are a standard of care therapy in castration-resistant prostate cancer (CRPC); however, mechanisms underlying the clinical activity of taxanes are poorly understood. Recent work suggests that the microtubule network of prostate cells is critical for androgen receptor nuclear translocation and activity. In this study, we used a set of androgen receptor deletion mutants to identify the microtubule-binding domain of the androgen receptor, which encompasses the DNA binding domain plus hinge region. We report that two clinically relevant androgen receptor splice variants, ARv567 and ARv7, differentially associate with microtubules and dynein motor protein, thereby resulting in differential taxane sensitivity in vitro and in vivo. ARv7, which lacks the hinge region, did not co-sediment with microtubules or coprecipitate with dynein motor protein, unlike ARv567. Mechanistic investigations revealed that the nuclear accumulation and transcriptional activity of ARv7 was unaffected by taxane treatment. In contrast, the microtubule-interacting splice variant ARv567 was sensitive to taxane-induced microtubule stabilization. In ARv567-expressing LuCap86.2 tumor xenografts, docetaxel treatment was highly efficacious, whereas ARv7-expressing LuCap23.1 tumor xenografts displayed docetaxel resistance. Our results suggest that androgen receptor variants that accumulate in CRPC cells utilize distinct pathways of nuclear import that affect the antitumor efficacy of taxanes, suggesting a mechanistic rationale to customize treatments for patients with CRPC, which might improve outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84899497770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899497770&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-2876

DO - 10.1158/0008-5472.CAN-13-2876

M3 - Article

C2 - 24556717

AN - SCOPUS:84899497770

VL - 74

SP - 2270

EP - 2282

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 8

ER -